文献速递乳腺癌放疗姑息放疗与转移瘤

同期放疗联合每周紫杉醇治疗不可切除局部区域复发乳腺癌的前瞻性结果

Prospective results of concurrent radiation therapy and weekly paclitaxel as salvage therapy for unresectable locoregionally recurrent breast cancer.
PubMed 文献 · Radiat Oncol · 2019-07-02

这项前瞻性单中心研究纳入51例乳房切除术后不可切除局部区域复发乳腺癌患者,采用复发灶60 Gy/30次放疗同期每周紫杉醇50 mg/m2×5周方案。临床缓解率达92.2%(完全缓解70.6%),2年与5年累计局部无进展生存率分别为62.8%和53.0%,未观察到4级毒性。

要点

  • 同期放疗联合每周紫杉醇治疗不可切除局部区域复发乳腺癌临床缓解率达92.2%。
  • 2年和5年累计局部无进展生存率分别为62.8%和53.0%。
  • 未观察到4级毒性,3级放射性皮炎和白细胞减少发生率分别为19.6%和23.5%。

核心结论

  • 同期放疗联合每周紫杉醇可作为乳房切除术后不可切除局部区域复发乳腺癌的有效治疗选择,毒性可接受。

研究设计与样本

  • 前瞻性单中心研究,纳入2008至2012年诊治的51例乳房切除术后不可切除局部区域复发乳腺癌患者。
  • 放疗剂量为60 Gy分30次照射复发灶,化疗为每周紫杉醇50 mg/m2共5周。
  • 治疗前2年每3个月、之后每6个月行临床检查及CT或PET/CT,采用RECIST标准评估肿瘤缓解,放疗期间每周按NCI常见毒性标准3.0版评估毒性。

主要发现

  • 51例患者共61个复发灶,中位年龄49岁;胸壁20例(32.8%)、锁骨上19例(31.1%)、腋窝11例(18.0%)、内乳淋巴结11例(18.0%)。
  • 复发表现为单发25例、多发20例、弥漫生长6例。
  • 临床缓解47例(92.2%),其中完全缓解36例(70.6%)、部分缓解11例(21.6%);疾病稳定2例(3.9%)、疾病进展2例。
  • 治疗后2年与5年累计局部无进展生存率分别为62.8%和53.0%。
  • 未观察到4级毒性;3级放射性皮炎10例(19.6%)、3级白细胞减少12例(23.5%),1例发生2级肺炎。

关键数值与推荐

  • 放疗剂量60 Gy分30次,同期每周紫杉醇50 mg/m2共5周。
  • 肿瘤缓解采用RECIST标准评估,毒性采用NCI常见毒性标准3.0版每周评估。

临床怎么用

  • 对乳房切除术后不可切除局部区域复发乳腺癌,可考虑同期放疗联合每周紫杉醇方案。
  • 治疗期间需每周评估毒性,重点关注放射性皮炎和白细胞减少。

局限性

  • 本研究为单中心前瞻性研究,样本量51例。
  • 原文未报告随机对照比较或长期总生存结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the efficacy and toxicity of concurrent radiation therapy (RT) and paclitaxel in the treatment of unresectable locoregionally recurrent breast cancer (RBC) after mastectomy as primary treatment. METHODS: This was a prospective monocentric study of 51 patients (pts) diagnosed with unresectable locoregionally RBC after mastectomy and treated between 2008 and 2012. Radiotherapy (RT) was delivered at 60 Gy in 30 treatment fractions to recurrent sites. Chemotherapy was weekly paclitaxel of 50 mg/m2 for 5 weeks. All pts. underwent clinical examination, CT or PET/CT every 3 months in first 2 years and then every 6 months. Tumor response was evaluated clinically and by CT using the RECIST criteria. Toxicity was assessed weekly during RT by the NCI common toxicity criteria (version 3.0). RESULTS: Fifty-one pts. with 61 recurrent sites were studied. The median age was 49 years. Sites of RBC were chest wall in 20 patients (32.8%), supraclavicular in 19 (31.1%), axilla in 11 (18.0%), and internal mammary lymph nodes in the remaining 11 (18.0%). RBC presented as single in 25 pts., multiple in 20 pts. and diffuse growth in 6 pts. Clinical response was observed in 47 pts. (92.2%), with 36 (70.6%) complete and 11 (21.6%) partial responses. Two patients (3.9%) presented with stable disease and 2 progressive disease. The cumulative local progression-free survival rate was 62.8% at 2 year and 53.0% at 5 years after treatment. No grade 4 toxicity was observed. Grade 3 radiation dermatitis and leukocytopenia were observed in 10 (19.6%) and 12 (23.5%) pts., respectively. One patient experienced grade 2 pneumonitis. CONCLUSIONS: Concurrent RT and weekly paclitaxel could be an effective therapeutic option for unresectable locoregionally recurrent breast cancer after mastectomy with an acceptable toxicity profile.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Cai G, Cao L, Kirova YM, et al. Prospective results of concurrent radiation therapy and weekly paclitaxel as salvage therapy for unresectable locoregionally recurrent breast cancer. Radiat Oncol. 2019. PMID: 31266510. doi:10.1186/s13014-019-1321-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。